FRONTIERS IN ENDOSCOPY, SERIES #41Use of Volumetric Laser Endomicroscopy in the Esophagus
Advanced or optical imaging in the esophagus allows for a detailed view of the esophagus at a level beyond white light endoscopy. The newest commercially available endoscopic advanced imaging tool is volumetric laser endomicroscopy (VLE) or second-generation optical coherence tomography. VLE is currently being used in management of Barrett's esophagus, squamous cell dysplasia and cancer of the esophagus, and during peroral endoscopic myotomy. This review describes VLE and its current clinical applications to the esophagus.
NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #172Amyloid - A Wolf in Sheep's Clothing
Amyloidosis is a complex group of diseases associated with variable presentations characterized by excessive deposition of the misfolded, abnormal, and insoluble proteins in different organs of the body. The goal of management in amyloidosis is to inhibit the excessive production of amyloid fibrils and control symptoms. This article highlights classification, etiologies, diagnosis, and management of amyloidosis, in particular, the management of GI symptoms and malnutrition.
Cholera Vaccine and Colorectal Cancer
Since cholera toxin can act as a modulator of the immune response with anti-inflammatory effects and reduces development of colon polyps in mouse models of colorectal cancer (CRC), a population-based study to determine in patients with CRC, whether subsequent administration of that vaccine (killed Vibrio cholerae 01 whole cells and recombinant cholera toxin B subunit) affects mortality.
Cancer Treatment with Active Hepatitis C
HCV reactivation in patients receiving cancer treatment has been reported in retrospective studies. To determine prospectively the incidence, predictors, and clinical significance of HCV reactivation during cancer treatment, HCV-affected patients receiving treatment between November 2012 and July 2016 were studied. Reactivation was defined as an increase in HCV RNA greater than 1 log10 IU/mL over baseline and hepatitis flare as an increase in ALT to greater than 3 times the upper limits of normal.
SYNERGY PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF TRULANCE® (PLECANATIDE) FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN ADULTS
NEW YORK - Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced that the U.S. Food and Drug Administration (FDA) has approved TRULANCE® (plecanatide) 3 mg tablet for the once-daily treatment of irritable bowel syndrome with constipation (IBS-C) in adults. This is the second indication for TRULANCE, which is already approved for the treatment of adults with chronic idiopathic constipation (CIC).
TAKEDA UTILIZES SOCIAL MEDIA ANALYSIS AND SURVEY IN A STUDY TO BETTER UNDERSTAND PATIENT PREFERENCES WHEN SEEKING TREATMENT FOR INFLAMMATORY BOWEL DISEASE
Study shows treatment decision-making is highly personalized, with close to 98% of patients expressing unique decision-making profiles; online support tool resulting from study supports personalized treatment selection for patients with providers